StockData
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. (ACRV) stock

ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $61.28MP/E –Yield –

Acrivon Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Acrivon Therapeutics

Acrivon Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Acrivon Therapeutics figures

See a number that looks wrong?